Ampersand Capital Partners Acquires Biologos LLC
March 19, 2024
Ampersand Capital Partners, a healthcare-focused private equity firm, has acquired Biologos LLC, a Glendale Heights, Illinois-based manufacturer of custom and standard cell culture media, reagents, buffers, enzymes, and sera. Ampersand will invest to expand Biologos' capabilities, product offerings, and geographic reach, and has appointed Frank Witney as Chairman with two Ampersand principals joining the board.
- Buyers
- Ampersand Capital Partners
- Targets
- Biologos LLC
- Industry
- Biotechnology
- Location
- Illinois, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Ampersand Capital Partners Invests in Genezen Laboratories
January 5, 2021
Biotechnology
Ampersand Capital Partners has made a majority growth-equity investment in Genezen Laboratories, a cell and gene therapy CDMO, to fund completion of a 25,000 sq. ft. cGMP lentiviral vector production facility and expand process development and analytical testing capabilities. The capital will support Genezen's capability expansion across upstream/downstream processing, analytical testing, and cGMP vector production to serve early‑phase and growth-stage cell and gene therapy developers.
-
Ampersand Capital Partners Invests in BioEcho Life Sciences
March 1, 2022
Biotechnology
Ampersand Capital Partners made a minority growth equity investment in Cologne-based BioEcho Life Sciences to support the company's global expansion, new product launches, and expansion of its direct salesforce. As part of the transaction Ampersand appointed Frank Witney and Arya Mehrabanzad to BioEcho's board; financial terms were not disclosed.
-
Ampersand Capital Partners Invests in AnaBios Corporation
June 7, 2022
Healthcare Services
Ampersand Capital Partners has made a growth equity investment in San Diego-based AnaBios Corporation, a preclinical contract research organization specializing in translational research using human tissues. The investment will be used to expand AnaBios’s capabilities, therapeutic area coverage and global reach to support more successful drug discovery and development programs.
-
Ampersand Capital Partners Makes Growth Investment in Vibalogics GmbH
May 29, 2019
Biotechnology
Ampersand Capital Partners has made a growth equity investment in Vibalogics GmbH, a German CDMO specializing in development and GMP manufacturing of complex viral products. The investment will fund expansion of Vibalogics' process development and manufacturing capabilities and support broader growth in the U.S. and European markets.
-
Ampersand Capital Partners Leads $18.5M Growth Investment in Genezen
November 2, 2023
Biotechnology
Genezen closed an $18.5 million follow-on growth equity financing led by Ampersand Capital Partners to accelerate expansion of its viral vector development and GMP manufacturing capabilities. The capital will support build-out and technology investments at Genezen's facilities (including the Fishers, Indiana GMP viral vector site) to scale retroviral, lentiviral and AAV vector production and support additional customer programs.
-
Ampersand Capital Partners Makes Growth Investment in VIVEbiotech
December 4, 2024
Biotechnology
Ampersand Capital Partners has made a growth equity investment in VIVEbiotech to support expansion of the company’s lentiviral vector development and GMP manufacturing capabilities in San Sebastián, Gipuzkoa, Spain. The investment will fund capacity growth and execution of VIVEbiotech’s pipeline of customer projects for cell and gene therapy developers, and industry veteran Dr. Stefan Beyer has been named Chairman.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.